Please verify your age.
Germany's April 2024 reform legalised possession and home growing but never built a legal market. We look at what two years of real-world data reveal: why home cultivation thrived, why the social clubs stalled, how medical prescriptions exploded, and what growers elsewhere should take from it.
More than 1,000 medicinal cannabis products sit on pharmacy shelves, but only two have ever passed full regulatory assessment. We look at how special access pathways became the norm, what that gap means for patients and prescribers, and why honest genetics matter more than ever.
Asia's most permissive cannabis market is being rebuilt as a prescription system, and thousands of dispensaries have already gone. Here's why Thailand hit the handbrake, what it tells us about maturing markets from Canada to Spain, and why stable genetics matter more than ever.
The Czech Republic didn't build a legal weed market in 2024 — it built a three-plant home grow allowance. Here's what the reform actually changed, what stayed criminal, and why a hard plant count makes feminized and autoflowering genetics the smartest choice for your next run.
Europe